ADRB3 adrenoceptor beta 3
ENSG00000188778 · protein coding · Open Targets profile
G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent pathway, respectively (PubMed:10188996, PubMed:2570461, PubMed:8641219). The rank order of potency for physiological agonists is norepinephrine > epinephrine (PubMed:10188996, PubMed:2570461, PubMed:8641219). Involved in the regulation of thermogenesis and lipolysis in brown and white adipose tissue, after coupling to G(s) proteins and stimulation of the cAMP-PKA axis (By similarity). Also activates lipolytic process by coupling to G(i) proteins and consequent initiation of the ERK1/2 MAP kinase cascade (PubMed:10207024). Participates in relaxation of the blood vessels and the urinary bladder (PubMed:10188996). Also mediates negative inotropic effects in cardiomyocytes through activation of an NO synthase pathway and subsequent increase in cGMP levels, possibly involving G(i/o) protein-mediated coupling (PubMed:9769330). {ECO:0000250|UniProtKB:P25962, ECO:0000269|PubMed:10188996, ECO:0000269|PubMed:10207024, ECO:0000269|PubMed:2570461, ECO:0000269|PubMed:8641219, ECO:0000269|PubMed:9769330}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
gnomAD loss of function constraint: o/e 1.3847999572753906 (upper bound 1.8516000509262085). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against ADRB3 (carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrine), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Jennifer C NaylorDurham VA Medical Center, Durham, NC · 3 of 3 trials Phase 2+
- Christine E. MarxDurham VA Medical Center, Durham, NC · 2 of 2 trials Phase 2+
- Irina BancosMayo Clinic · 2 of 2 trials Phase 2+
- Parag GoyalWeill Medical College of Cornell University · 2 of 2 trials Phase 2+
- Principal InvestigatorImmedica Pharma AB · 2 of 2 trials Phase 2+
- Ashish KhannaWake Forest University Health Sciences · 1 of 2 trials Phase 2+
- Lynnette K NiemanNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 of 2 trials Phase 2+
- Manoj K KarmakarChinese University of Hong Kong · 1 of 2 trials Phase 2+
- Aditi BagchiSt. Jude Children's Research Hospital · 1 of 1 trials Phase 2+
- Afua GyamfiAtrium Health Wake Forest Baptist · 1 of 1 trials Phase 2+
- Alan TN TitaUniversity of Alabama at Birmingham · 1 of 1 trials Phase 2+
- Albert AssadIncyte Corporation · 1 of 1 trials Phase 2+
- Alice MimsBeat AML · 1 of 1 trials Phase 2+
- Amir HamrahianJohns Hopkins University · 1 of 1 trials Phase 2+
- Andrea BiondiEsPhALL Network/ BFM Study Group · 1 of 1 trials Phase 2+
Registry trials of carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrine updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 322 of 372 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 28 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
516 trials of drugs against ADRB3 were stopped early; 4 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrine, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 516.
- terminated · 2026-10-28 · Algemeen Ziekenhuis Maria Middelares · Norepinephrine (static group), Norepinephrine (dynamic group)“The planned interim analysis revealed greater variability than expected, requiring a larger sample size. Given the limited eligible population, recruitment was deemed infeasible within a reasonable timeframe, leading to study termination.”
- withdrawn · 2026-10-28 · Aarhus University Hospital · matched by the registry's drug synonymsNo reason given
- terminated · 2026-10-23 · Vanderbilt University Medical Center · matched by the registry's drug synonyms“enrollment goal was not met.”
- terminated · 2026-10-22 · Cynata Therapeutics Limited · matched by the registry's drug synonyms“Cynata Therapeutics has taken the decision to discontinue the study following the Primary Evaluation period analysis. The results did not demonstrate the anticipated clinical benefit of CYP-001 in combination with corticosteroids in HR-aGVHD.”
- terminated · 2026-10-16 · Insel Gruppe AG, University Hospital Bern · matched by the registry's drug synonyms“Terminated prematurely due to a lower-than-expected enrollment rate, making it unfeasible to reach the target population in a timely manner.”
- terminated · 2026-10-14 · Yale University · Norepinephrine“The study was terminated prematurely due to lack of continued funding.”
- terminated · 2026-10-06 · Janssen Research & Development, LLC · matched by the registry's drug synonyms“The study was Early Terminated as per Sponsor's decision (communicated to sites on 06Mar2025)”
- suspended · 2026-10-02 · Columbia University · matched by the registry's drug synonyms“lack of funding”
- withdrawn · 2026-09-14 · Neurocrine UK Limited · matched by the registry's drug synonyms“Protocol re-design required following EU Phase III results”
- terminated · 2026-09-09 · CAMC Health System · matched by the registry's drug synonyms“Lack of research personnel”
- withdrawn · 2026-08-31 · CAMC Health System · matched by the registry's drug synonyms“Study closed for PI failure to submit renewal paperwork”
- terminated · 2026-08-26 · SwanBio Therapeutics, Inc. · matched by the registry's drug synonyms“The SBT101 program for AMN was terminated for business/strategic reasons, and there were no safety concerns”
- suspended · 2026-08-25 · University of Southern California · matched by the registry's drug synonyms“Lower than expected enrollment rate”
- terminated · 2026-07-28 · Siriraj Hospital · matched by the registry's drug synonyms“The study was terminated early on December 25, 2025, following the Data and Safety Monitoring Board (DSMB) recommendation due to preliminary evidence of futility.”
- withdrawn · 2026-07-23 · University of Minnesota · matched by the registry's drug synonyms“Lack of Participants”
- terminated · 2026-07-07 · Boston Children's Hospital · matched by the registry's drug synonyms“Funding constraints”
- terminated · 2026-06-26 · University of Utah · matched by the registry's drug synonyms“Due to insurance changes for SIJ RFAs, enrollment was slow. The sponsor decided to end the study.”
- terminated · 2026-06-22 · University Hospital, Bordeaux · matched by the registry's drug synonyms“stop due to medication error with the placebo”
- suspended · 2026-06-22 · Rutgers, The State University of New Jersey · matched by the registry's drug synonyms“This study never got funded. It is not feasible to conduct this study without funding.”
- suspended · 2026-06-16 · Baptist Health South Florida · matched by the registry's drug synonyms“Funding”
- withdrawn · 2026-06-15 · University Hospital, Tours · matched by the registry's drug synonyms“COMPETITOR TEST (RECOVERY)”
- terminated · 2026-06-15 · Mayo Clinic · Carvedilol“slow accrual; insufficient funding to continue to accrue”
- withdrawn · 2026-06-12 · Rennes University Hospital · matched by the registry's drug synonyms“Investigator leaving the hospital”
- terminated · 2026-06-10 · Columbia University · matched by the registry's drug synonyms“Closed by the industry collaborator”
- terminated · 2026-06-04 · McMaster University · matched by the registry's drug synonyms“It was terminated because of poor recruitment rate.”
Paediatric incentives and obligations for ADRB3's drugs
For carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrine: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · ADRB3 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000221175 (vibegron, Treatment of myoneurogenic bladder disorders): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 16 Dec 2024; EMEA-001743-PIP01-14 (carvedilol;ivabradine hydrochloride, Treatment of heart failure;Treatment of ischaemic coronary artery disorders): W: decision granting a waiver in all age groups for all conditions or indications, 7 Aug 2015Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrineRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Obgemsa: authorised since 27 Jun 2024Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Obgemsa, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrineRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 771 interventional studies of carvedilol, hydroxyamphetamine hydrobromide, ephedrine, carteolol, mephentermine, isoproterenol, norepinephrine bitartrate, dipivefrin, vibegron, epinephrine bitartrate, labetalol, norepinephrine include patients under 18; 143 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 28 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.